Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding ...

The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.

J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...

Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Pasi A. Jänne, M.D., PhD, a world renowned translational thoracic medical oncologist, to its Scientific Advisory Board (SAB).

Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...